Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development

Radiotherapy is an effective anticancer treatment, but combinations with targeted agents that maximize efficacy while sparing normal tissue are needed. Here, we assess the radiopotentiation profiles of DNA damage response inhibitors (DDRi) olaparib (PARP1/2), ceralasertib (ATR), adavosertib (WEE1),...

Descripción completa

Detalles Bibliográficos
Autores principales: Gill, Sonja J., Wijnhoven, Paul W.G., Fok, Jacqueline H.L., Lloyd, Rebecca L., Cairns, Jonathan, Armenia, Joshua, Nikkilä, Jenni, Lau, Alan, Bakkenist, Christopher J., Galbraith, Susan M., Vens, Conchita, O'Connor, Mark J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Small Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650722/
https://www.ncbi.nlm.nih.gov/pubmed/34158341
http://dx.doi.org/10.1158/1535-7163.MCT-20-0502

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650722/
https://www.ncbi.nlm.nih.gov/pubmed/34158341
http://dx.doi.org/10.1158/1535-7163.MCT-20-0502

Ejemplares similares